Enanta Pharmaceuticals


Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta’s collaboration with AbbVie, have now been approved around the world as part of AbbVie’s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta’s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). Please visit www.enanta.com for more information.

United States



Virology Liver Disease

View Employees

Lijuan Jiang
Senior Director, Screening, DMPK and Bioanalysis at Enanta Pharmaceuticals
Jun Ma
Principal Investigator at Enanta Pharmaceuticals
Nathalie Adda
SVP, Chief Medical Officer at Enanta Pharmaceuticals
Jianming Yu
Principal Investigator at Enanta Pharmaceuticals
Jennifer Viera
Senior Director, Investor Relations and Corporate Communications at Enanta Pharmaceuticals
Bryan Goodwin
Vice President, Head of Biology at Enanta Pharmaceuticals
Jeffrey Higgins M.M.
Associate Director - Operations Management at Enanta Pharmaceuticals

Find more contacts